Asian Pacific Journal of Cancer Prevention

  • 제16권4호
  • /
  • Pages.1397-1401
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of Tbx3 Predicts Poor Prognosis of Patients with Resectable Pancreatic Carcinoma

  • Wang, Hong-Cheng (Department of General Surgery, Sixth People's Hospital Affiliated Shanghai Jiao Tong University) ;
  • Meng, Qing-Cai (Department of General Surgery, Sixth People's Hospital Affiliated Shanghai Jiao Tong University) ;
  • Shan, Ze-Zhi (Department of General Surgery, Sixth People's Hospital Affiliated Shanghai Jiao Tong University) ;
  • Yuan, Zhou (Department of General Surgery, Sixth People's Hospital Affiliated Shanghai Jiao Tong University) ;
  • Huang, Xin-Yu (Department of General Surgery, Sixth People's Hospital Affiliated Shanghai Jiao Tong University)
  • 발행 : 2015.03.09
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: To determine the expressions of Tbx3, a member of subgroup belonging to T-box family, and its prognostic value in pancreatic carcinoma. Materials and Methods: We determined the expression levels of Tbx3 on both mRNA and protein levels in 30 pairs of fresh tumor tissues and paratumor tissues by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting, respectively. In addition, protein level of Tbx3 were identified using immunochemistry in 80 pairs of paraffin-embedded specimen. The correlations between Tbx3 expression and various clinicopathological parameters as well as overall survival were evaluated. Results: Tbx3 mRNA and protein levels in tumor tissues were significantly higher than in the paratumor tissues by qRT-PCR ($0.05{\pm}0.007$ vs. $0.087{\pm}0.001$, p<0.001) and western blotting ($1.134{\pm}0.043$ vs. $0.287{\pm}0.017$, p<0.001). The statistical analysis based on immunohistochemical evaluation suggested that Tbx3 aberrant expression was significantly associated with several conventional clinicopathological variables, such as gender, age, tumor position, preoperative CA19-9 level, pathological T staging and N staging. Univariate and multivariate analyses revealed that Tbx3 expression was an independent prognostic factor for overall survival (<0.001). Conclusions: Our results suggest that overexpression of Tbx3 is associated with poor prognosis of pancreatic cancer patients. However, additional clinical trials are needed to accurately validate this observation.

키워드

참고문헌

  1. Ansari D, Rosendahl A, Elebro J, et al (2011). Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg, 98, 1041-55. https://doi.org/10.1002/bjs.7574
  2. Ballim RD, Mendelsohn C, Papaioannou VE, et al (2012). The ulnar-mammary syndrome gene, Tbx3, is a direct target of the retinoic acid signaling pathway, which regulates its expression during mouse limb development. Mol Biol Cell, 23, 2362-72. https://doi.org/10.1091/mbc.E11-09-0790
  3. Begum S, Papaioannou VE (2011). Dynamic expression of Tbx2 and Tbx3 in developing mouse pancreas. Gene Expr Patterns, 11, 476-83. https://doi.org/10.1016/j.gep.2011.08.003
  4. Carlson H, Ota S, Song Y, et al (2002). Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene, 21, 3827-35. https://doi.org/10.1038/sj.onc.1205476
  5. Cavard C, Audebourg A, Letourneur F, et al (2009). Gene expression profiling provides insights into the pathways involved in solid pseudopapillary neoplasm of the pancreas. J Pathol, 218, 201-9. https://doi.org/10.1002/path.2524
  6. Chapman DL, Garvey N, Hancock S, et al (1996). Expression of the T-box family genes, Tbx1-Tbx5, during early mouse development. Dev Dyn, 206, 379-90. https://doi.org/10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F
  7. Du HF, Ou LP, Yang X, et al (2014). A new PKCalpha/beta/TBX3/E-cadherin pathway is involved in PLCepsilonregulated invasion and migration in human bladder cancer cells. Cell Signal, 26, 580-93. https://doi.org/10.1016/j.cellsig.2013.11.015
  8. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49, 1374-403. https://doi.org/10.1016/j.ejca.2012.12.027
  9. Fillmore CM, Gupta PB, Rudnick JA, et al (2010). Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A, 107, 21737-42. https://doi.org/10.1073/pnas.1007863107
  10. Hansel DE, Rahman A, House M, et al (2004). Met protooncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in welldifferentiated pancreatic endocrine neoplasms. Clin Cancer Res, 10, 6152-8. https://doi.org/10.1158/1078-0432.CCR-04-0285
  11. Hidalgo M (2010). Pancreatic cancer. N Engl J Med, 362, 1605-17. https://doi.org/10.1056/NEJMra0901557
  12. Howard B, Ashworth A (2006). Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet, 2, 112. https://doi.org/10.1371/journal.pgen.0020112
  13. Ito A, Asamoto M, Hokaiwado N, et al (2005). Tbx3 expression is related to apoptosis and cell proliferation in rat bladder both hyperplastic epithelial cells and carcinoma cells. Cancer Lett, 219, 105-12. https://doi.org/10.1016/j.canlet.2004.07.051
  14. Kim J, Chu J, Shen X, et al (2008). An extended transcriptional network for pluripotency of embryonic stem cells. Cell, 132, 1049-61. https://doi.org/10.1016/j.cell.2008.02.039
  15. Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57. https://doi.org/10.1016/S0140-6736(04)15841-8
  16. Li J, Weinberg MS, Zerbini L, et al (2013). The oncogenic TBX3 is a downstream target and mediator of the TGF-beta1 signaling pathway. Mol Biol Cell, 24, 3569-76. https://doi.org/10.1091/mbc.E13-05-0273
  17. Lomnytska M, Dubrovska A, Hellman U, et al (2006). Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer, 118, 412-21. https://doi.org/10.1002/ijc.21332
  18. Lyng H, Brovig RS, Svendsrud DH, et al (2006). Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics, 7, 268. https://doi.org/10.1186/1471-2164-7-268
  19. Minguillon C, Logan M (2003). The comparative genomics of T-box genes. Brief Funct Genomic Proteomic, 2, 224-33. https://doi.org/10.1093/bfgp/2.3.224
  20. Mowla S, Pinnock R, Leaner VD, et al (2011). PMA-induced up-regulation of TBX3 is mediated by AP-1 and contributes to breast cancer cell migration. Biochem J, 433, 145-53. https://doi.org/10.1042/BJ20100886
  21. Muller CW, Herrmann BG (1997). Crystallographic structure of the T domain-DNA complex of the Brachyury transcription factor. Nature, 389, 884-8. https://doi.org/10.1038/39929
  22. Peres J, Davis E, Mowla S, et al (2010). The Highly Homologous T-Box Transcription Factors, TBX2 and TBX3, Have Distinct Roles in the Oncogenic Process. Genes Cancer, 1, 272-82. https://doi.org/10.1177/1947601910365160
  23. Renard CA, Labalette C, Armengol C, et al (2007). Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res, 67, 901-10. https://doi.org/10.1158/0008-5472.CAN-06-2344
  24. Rodriguez M, Aladowicz E, Lanfrancone L, et al (2008). Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res, 68, 7872-81. https://doi.org/10.1158/0008-5472.CAN-08-0301
  25. Rowley M, Grothey E, Couch FJ (2004). The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia, 9, 109-18. https://doi.org/10.1023/B:JOMG.0000037156.64331.3f
  26. Schmalhofer O, Brabletz S, Brabletz T (2009). E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev, 28, 151-66. https://doi.org/10.1007/s10555-008-9179-y
  27. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  28. Washkowitz AJ, Gavrilov S, Begum S, et al (2012). Diverse functional networks of Tbx3 in development and disease. Wiley Interdiscip Rev Syst Biol Med, 4, 273-83. https://doi.org/10.1002/wsbm.1162
  29. Winter JM, Yeo CJ, Brody JR (2013). Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol, 107, 15-22. https://doi.org/10.1002/jso.23192
  30. Yan W, Cao QJ, Arenas RB, et al (2010). GATA3 inhibits breast cancer metastasis through the reversal of epithelialmesenchymal transition. J Biol Chem, 285, 14042-51. https://doi.org/10.1074/jbc.M110.105262
  31. Zhang JF, He ML, Qi D, et al (2011). Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via Tbx3 suppression. Integr Cancer Ther, 10, 85-91. https://doi.org/10.1177/1534735410373921

피인용 문헌

  1. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer vol.114, pp.10, 2016, https://doi.org/10.1038/bjc.2016.73
  2. T-box 3 overexpression is associated with poor prognosis of non-small cell lung cancer vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5855